Serological correlate of protection against norovirus-induced gastroenteritis.
BACKGROUND
Norovirus infection is the leading cause of acute nonbacterial gastroenteritis. Histoblood group antigens (HBGAs) are host susceptibility determinants for Norwalk virus (NV) infection. We hypothesized that antibodies that block NV-HBGA binding are associated with protection from clinical illness following NV exposure.


METHODS
We developed an HBGA blocking assay to examine the ability of human serum to block the interaction of NV viruslike particles with H type 1 and H type 3 glycans. Serum samples from persons who were experimentally challenged with NV were evaluated.


RESULTS
There was a high correlation between the H type 1 and H type 3 synthetic glycan assays (r = 0.977; P < .001); the H type 1 assay had higher quantitative sensitivity (P < .001). Among 18 infected secretor-positive individuals, blocking titers peaked by day 28 after challenge and were higher for individuals who did not develop gastroenteritis than for those who developed gastroenteritis on days 0, 14, 28, and 180 (P < .05 for each). In addition, 6 of 6 subjects without gastroenteritis had measurable prechallenge blocking titers (>25), compared with 2 of 12 subjects with gastroenteritis (P = .002).


CONCLUSIONS
Blocking antibodies correlate with protection against clinical NV gastroenteritis. This knowledge will help guide the evaluation of new vaccine strategies and the elucidation of the nature of immunity to the virus. Trial registration. ClinicalTrials.gov identifier: NCT00138476.
Reeck
Amanda
A
Departments of Molecular Virology, Baylor College of Medicine, Houston, Texas, USA.
Kavanagh
Owen
O
Estes
Mary K
MK
Opekun
Antone R
AR
Gilger
Mark A
MA
Graham
David Y
DY
Atmar
Robert L
RL
D000293:Adolescent; D000328:Adult; D019138:Antibodies, Blocking / Q000097:blood / Q000276:immunology*; D001681:Biological Assay / Q000379:methods; D017250:Caliciviridae Infections / Q000097:blood / Q000276:immunology*; D005759:Gastroenteritis / Q000276:immunology* / Q000821:virology*; D006801:Humans; D008875:Middle Aged; D009663:Norwalk virus / Q000276:immunology*; D011134:Polysaccharides / Q000276:immunology; D015203:Reproducibility of Results; D017201:Virus Shedding; D055815:Young Adult
D019138:Antibodies, Blocking; D011134:Polysaccharides
Trends Microbiol. 2004 Jun;12(6):279-87
15165606
J Virol. 2002 Dec;76(23):12335-43
12414974
J Clin Microbiol. 1994 Dec;32(12):3059-63
7883902
Nat Rev Microbiol. 2010 Mar;8(3):231-41
20125087
Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9175-80
18599458
J Virol. 1992 Nov;66(11):6527-32
1328679
Trends Microbiol. 2005 Jun;13(6):285-93
15936661
Mol Immunol. 2009 Sep;46(15):3037-49
19608278
J Infect Dis. 1982 Apr;145(4):483-9
6279734
J Infect Dis. 1995 Mar;171(3):566-9
7876602
J Virol. 1996 Oct;70(10):6589-97
8794293
Emerg Infect Dis. 2008 Oct;14(10):1553-7
18826818
Gastroenterol Clin North Am. 2006 Jun;35(2):275-90, viii
16880066
N Engl J Med. 1977 Jul 14;297(2):86-9
405590
J Virol. 2010 Feb;84(4):1800-15
20007270
Gastroenterology. 2002 Jun;122(7):1967-77
12055602
J Clin Microbiol. 1993 Aug;31(8):2185-91
8396590
J Infect Dis. 1984 Oct;150(4):531-4
6092484
J Infect Dis. 1985 Jan;151(1):99-105
2981278
Nat Med. 2003 May;9(5):548-53
12692541
J Infect Dis. 1994 Jul;170(1):34-43
8014518
Br J Haematol. 2005 Sep;130(6):954-63
16156865
J Virol. 2005 Jun;79(11):6714-22
15890909
Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25
10511517
Pediatrics. 2009 Dec;124(6):1633-41
19933727
J Infect Dis. 1990 Jan;161(1):18-21
2153184
Vaccine. 2006 Jun 12;24(24):5220-34
16650512
J Virol. 2002 Mar;76(6):3023-30
11861868
J Virol. 2008 Nov;82(21):10756-67
18701592
J Virol. 2009 Jun;83(11):5363-74
19297483
J Virol. 2003 Jan;77(1):405-15
12477845
J Med Virol. 2005 Sep;77(1):116-20
16032732
J Infect Dis. 2002 May 1;185(9):1335-7
12001052